Enteral Supplementation With Docosahexaenoic Acid and Arachidonic Acid (DHA-AA) in Preterm Infants

Launched by HOSPITAL UNIVERSITARI VALL D'HEBRON RESEARCH INSTITUTE · Apr 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of giving preterm infants special nutrients called docosahexaenoic acid (DHA) and arachidonic acid (AA), which are important for brain development and overall health. Researchers believe that these nutrients can help prevent health problems in newborns who are born too early. The goal is to safely increase the levels of DHA in the baby's blood while keeping the right balance with AA over the first few weeks of life.

To take part in this study, babies need to be born between 23 and 32 weeks of pregnancy and be admitted to the Neonatology Department at Vall d'Hebron University Hospital in Barcelona. Parents or guardians must provide consent for their participation. The study will involve giving the infants these nutrients through feeding for about 30 days, and it aims to monitor their health and development during this time. This trial is currently recruiting participants, and it is important for families to discuss with their healthcare providers to see if this study is a good fit for their baby.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newborns with a gestational age between 23 and 32 weeks admitted to the Neonatology Service of the Vall d'Hebron University Hospital and with informed consent signed by the parents or legal guardians.
• Exclusion Criteria:
• • Severe malformation incompatible with life.
• • Impossibility of enteral nutrition during the expected duration of the study (30 days).